Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008175 | Lung Neoplasms NIH | 0.29 |
| D009369 | Neoplasms, NIH | 0.17 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100526 | Neoplasm of the lung HPO | 0.29 |
| HP:0002664 | Neoplasm HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors believe both are good treatments and are therefore conducting this study to determine if one may be possibly better than the other.
Description: Survival estimates will include death from any cause.
Measure: Overall Survival Time: From date of randomization through study completion, up to 10 yearsDescription: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and Lung Cancer (LC 13) survey instruments will assess patients' general state of physical, social/family, emotional and functional well-being.
Measure: Patient reported health-related quality of life Time: 5 yearsDescription: The St George's Respiratory Questionnaire will evaluate respiratory symptoms, activity limitations from breathlessness, and impact of respiratory function on social and psychological functioning.
Measure: Respiratory Symptoms Time: 5 yearsDescription: The EQ-5D-5L (EuroQOL-5D) survey will measure quality adjusted life years.
Measure: Health State Utilities Time: 5 yearsDescription: Cause of death will be determined by an independent adjudication committee.
Measure: Lung cancer mortality Time: From date of randomization until date of death from any cause, assessed up to 10 years.Description: Post-treatment surveillance imaging will evaluate patients every 6 months for local, regional, and/or distant disease control.
Measure: Tumor patterns of failure Time: 5 yearsDescription: The Forced Expiratory Volume at 1 second (FEV1) will evaluate an objective measure of breathing function.
Measure: Respiratory Function Time: 5 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports